F. Hoffmann-La Roche Ltd: Data at the 2022 ASCO Annual Meeting highlight Roche's continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading
Source: finanznachrichten.de